ArticleBMC pediatrics2025
Early aminophylline is a potential therapy for preventing bronchopulmonary dysplasia in premature infants: a retrospective study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAminophylline is commonly used to treat apnea in premature infants. However, its impact on long-term complications in preterm infants is unclear.This retrospective study aimed to evaluate the effects and safety of early aminophylline in premature infants.
methodThis was a retrospective study including infants with a gestational age < 32 weeks and weight < 1500 g born in Nanfang hospital between January 2017 to December 2021 who were received early aminophylline or late aminophylline, clinical data were collected.
resultsOf the 296 selected infants, there were 208 in the early aminophylline group and 88 in the late aminophylline group. The incidence of bronchopulmonary dysplasia (BPD) was significantly lower in the early aminophylline group. Stratified by gestational age, the early aminophylline group had shorter durations of invasive mechanical ventilation and oxygen therapy in the "GA < 28" subgroup. Similarly, the "28 ≤ GA < 30" and "30 ≤ GA < 32" subgroups showed lower incidence of BPD, as well as shorter durations of ventilation and oxygen therapy. There were no significant differences in adverse reactions.
conclusionIn conclusion, early use of aminophylline may be associated with a decreased incidence of BPD in premature infants without significant adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.